Your session is about to expire
← Back to Search
Nivolumab for Esophageal Cancer (CheckMate 577 Trial)
CheckMate 577 Trial Summary
This trial will test whether the drug Nivolumab can help people with cancer live longer without their disease coming back.
CheckMate 577 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCheckMate 577 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533CheckMate 577 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had surgery for cancer with clear margins but still have some disease left.I finished chemo and radiation before surgery.My cancer is in the esophagus or where the stomach meets the esophagus, and it's at an advanced stage but not the most severe.
- Group 1: Nivolumab
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are some of the diseases that Nivolumab has been known to help with?
"Nivolumab is most often used to target and treat malignant neoplasms; however, it has also been found helpful in treating other conditions such as unresectable melanoma, squamous cell carcinoma, metastatic esophageal adenocarcinoma."
Are trial participants still being enrolled in this research?
"This particular trial is not currently enrolling patients. However, there are 749 other trials for Nivolumab that are actively recruiting participants. Out of all the cancer trials, 162 of them are admitting patients that have advanced cancer."
Do we have a historical precedent for Nivolumab's effectiveness?
"There are 749 ongoing trials regarding Nivolumab, with the majority of these being Phase 3 studies. Out of all the locations conducting research on Nivolumab, 84 percent of them are located in Basel, BE."
Is this research project a new one?
"There are presently 749 active studies for Nivolumab across 2347 cities and 50 countries. The earliest trial for Nivolumab was conducted in 2010 by Medarex. This Phase 1 drug approval stage involved 127 patients and completed its clinical trials in 2010. Since then, 18518 additional trials have been conducted worldwide."
Are there many facilities testing this medication in North America?
"There are a total of 94 medical centres where this trial is being conducted. This includes Local Institution - 0247 in Denver, Pacific Hematology Oncology Associates in San Francisco, and Local Institution - 0250 in Tucson."
What are the dangers that have been associated with taking Nivolumab?
"Nivolumab's safety is denoted by a score of 3. This means that it has gone through multiple phase 3 trials, which provides efficacy data and supports the medication's safety."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger